New England Journal of Medicine· 2021Q1

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Juan P. Frías, Melanie J. Davies, Julio Rosenstock, Federico C. Pérez Manghi et al.

1,911citations
Q1SCImago
2021year

Short summary

Once-weekly tirzepatide (5, 10, or 15 mg) significantly lowered glycated hemoglobin (HbA1c) by up to 2.30 percentage points versus 1.86 points for semaglutide (1 mg) over 40 weeks in patients with type 2 diabetes, demonstrating superiority and greater weight loss.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine